Skip to main content

No evidence of a detrimental effect of pitavastatin on neurocognitive function among people with HIV.

Publication ,  Journal Article
Erlandson, KM; McKhann, A; Kitch, DW; Palella, FJ; Ellis, RJ; Ances, BM; Zanni, MV; Diggs, MR; Chu, SM; Currier, JS; Bloomfield, GS; Aberg, JA ...
Published in: AIDS
November 1, 2025

OBJECTIVE: Effects of statins on neurocognitive function remain poorly understood, with some studies suggesting harm and others suggesting benefit. Limited observational data among people with HIV (PWH) is biased by indication for statin prescription. We sought to assess statin effects on neurocognitive function among PWH. DESIGN: We leveraged data from participants co-enrolled in REPRIEVE (randomized trial of pitavastatin vs. placebo among PWH with low-to-moderate cardiovascular risk) and HAILO (observational study involving repeated neurocognitive measures). METHODS: Participants with at least one measure of neurocognitive function before and after REPRIEVE randomization were included. Neurocognitive function was determined by NPZ-4, the average of the Z scores from Hopkins Verbal Learning Test Revised, Trailmaking A and B, and Digit Symbol Test every 48 weeks. Trajectories before and after randomization were analyzed with generalized estimating equation models. RESULTS: Of 181 co-enrolled participants (pitavastatin 88, placebo 93), changes over median 2.3 years on overall and individual neurocognitive scores were small, not meeting a clinically relevant threshold of more than 0.5/year, and similar between arms. Although subgroup analyses were limited by a small sample size, we observed trends toward improved Trailmaking A in participants with baseline impairment who were randomized to pitavastatin vs. placebo and towards worsened NPZ-4 in women randomized to pitavastatin vs. placebo that similarly did not reach threshold for clinical relevance. Other subgroup effects were minimal and not statistically or clinically significant. CONCLUSION: We found no evidence of a detrimental effect of pitavastatin use on a limited battery of neurocognitive assessments among PWH, even among PWH with baseline neurocognitive impairment.

Duke Scholars

Published In

AIDS

DOI

EISSN

1473-5571

Publication Date

November 1, 2025

Volume

39

Issue

13

Start / End Page

1913 / 1919

Location

England

Related Subject Headings

  • Virology
  • Quinolines
  • Placebos
  • Middle Aged
  • Male
  • Hydroxymethylglutaryl-CoA Reductase Inhibitors
  • Humans
  • HIV Infections
  • Female
  • Adult
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Erlandson, K. M., McKhann, A., Kitch, D. W., Palella, F. J., Ellis, R. J., Ances, B. M., … Grinspoon, S. K. (2025). No evidence of a detrimental effect of pitavastatin on neurocognitive function among people with HIV. AIDS, 39(13), 1913–1919. https://doi.org/10.1097/QAD.0000000000004267
Erlandson, Kristine M., Ashley McKhann, Douglas W. Kitch, Frank J. Palella, Ronald J. Ellis, Beau M. Ances, Markella V. Zanni, et al. “No evidence of a detrimental effect of pitavastatin on neurocognitive function among people with HIV.AIDS 39, no. 13 (November 1, 2025): 1913–19. https://doi.org/10.1097/QAD.0000000000004267.
Erlandson KM, McKhann A, Kitch DW, Palella FJ, Ellis RJ, Ances BM, et al. No evidence of a detrimental effect of pitavastatin on neurocognitive function among people with HIV. AIDS. 2025 Nov 1;39(13):1913–9.
Erlandson, Kristine M., et al. “No evidence of a detrimental effect of pitavastatin on neurocognitive function among people with HIV.AIDS, vol. 39, no. 13, Nov. 2025, pp. 1913–19. Pubmed, doi:10.1097/QAD.0000000000004267.
Erlandson KM, McKhann A, Kitch DW, Palella FJ, Ellis RJ, Ances BM, Zanni MV, Diggs MR, Chu SM, Currier JS, Bloomfield GS, Malvestutto CD, Fichtenbaum CJ, Aberg JA, Koletar SL, Presti RM, Hatlen TJ, Skiest DJ, Douglas PS, Ribaudo HJ, Grinspoon SK. No evidence of a detrimental effect of pitavastatin on neurocognitive function among people with HIV. AIDS. 2025 Nov 1;39(13):1913–1919.

Published In

AIDS

DOI

EISSN

1473-5571

Publication Date

November 1, 2025

Volume

39

Issue

13

Start / End Page

1913 / 1919

Location

England

Related Subject Headings

  • Virology
  • Quinolines
  • Placebos
  • Middle Aged
  • Male
  • Hydroxymethylglutaryl-CoA Reductase Inhibitors
  • Humans
  • HIV Infections
  • Female
  • Adult